CA3121615A1 - Combination taxoid nanoemulsion with immunotherapy in cancer - Google Patents

Combination taxoid nanoemulsion with immunotherapy in cancer Download PDF

Info

Publication number
CA3121615A1
CA3121615A1 CA3121615A CA3121615A CA3121615A1 CA 3121615 A1 CA3121615 A1 CA 3121615A1 CA 3121615 A CA3121615 A CA 3121615A CA 3121615 A CA3121615 A CA 3121615A CA 3121615 A1 CA3121615 A1 CA 3121615A1
Authority
CA
Canada
Prior art keywords
sbt
oil
tumor
cancer
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121615A
Other languages
English (en)
French (fr)
Inventor
James E. Egan
Mansoor Amiji
Iwao Ojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targagenix Inc
Northeastern University Boston
Research Foundation of the State University of New York
Original Assignee
Targagenix Inc
Northeastern University Boston
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc, Northeastern University Boston, Research Foundation of the State University of New York filed Critical Targagenix Inc
Publication of CA3121615A1 publication Critical patent/CA3121615A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3121615A 2017-12-20 2018-12-19 Combination taxoid nanoemulsion with immunotherapy in cancer Pending CA3121615A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762608015P 2017-12-20 2017-12-20
US62/608,015 2017-12-20
PCT/US2018/066465 WO2019126302A2 (en) 2017-12-20 2018-12-19 Combination taxoid nanoemulsion with immunotherapy in cancer

Publications (1)

Publication Number Publication Date
CA3121615A1 true CA3121615A1 (en) 2019-06-27

Family

ID=66815378

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121615A Pending CA3121615A1 (en) 2017-12-20 2018-12-19 Combination taxoid nanoemulsion with immunotherapy in cancer

Country Status (6)

Country Link
US (2) US11497713B2 (https=)
EP (1) EP3752130A4 (https=)
JP (2) JP7450888B2 (https=)
CN (1) CN112996501A (https=)
CA (1) CA3121615A1 (https=)
WO (1) WO2019126302A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214260A1 (en) * 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合
WO2022017666A1 (en) 2020-07-21 2022-01-27 F.Hoffmann-La Roche Ag Method of generating a metric to quantitatively represent an effect of a treatment
CN116173094A (zh) * 2023-03-15 2023-05-30 中南大学湘雅二医院 一种杜仲籽油在制备抗癌药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
CN1901901B (zh) 2003-10-30 2012-07-04 纽约州州立大学研究基金会 紫杉醇-脂肪酸结合物及其药物组合物
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
HRP20181187T1 (hr) * 2012-04-04 2018-09-21 Halozyme, Inc. Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor
KR20160132496A (ko) 2014-04-03 2016-11-18 인빅터스 온콜로지 피비티. 엘티디. 초분자 조합 치료제
WO2017214260A1 (en) * 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合

Also Published As

Publication number Publication date
WO2019126302A2 (en) 2019-06-27
JP2021517906A (ja) 2021-07-29
US12186428B2 (en) 2025-01-07
US20190183796A1 (en) 2019-06-20
EP3752130A4 (en) 2022-12-21
JP2024023463A (ja) 2024-02-21
US20230082272A1 (en) 2023-03-16
WO2019126302A3 (en) 2020-03-26
EP3752130A2 (en) 2020-12-23
US11497713B2 (en) 2022-11-15
CN112996501A (zh) 2021-06-18
JP7450888B2 (ja) 2024-03-18

Similar Documents

Publication Publication Date Title
US12186428B2 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
Attama et al. Nanogels as target drug delivery systems in cancer therapy: A review of the last decade
Guimaraes et al. Nanoparticles for immune cytokine TRAIL-based cancer therapy
Kiaie et al. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
El-Readi et al. Cancer nanomedicine: a new era of successful targeted therapy
Wei et al. Progress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor
Ma et al. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
Cui et al. Enhanced chemotherapeutic efficacy of paclitaxel nanoparticles co-delivered with microRNA-7 by inhibiting paclitaxel-induced EGFR/ERK pathway activation for ovarian cancer therapy
Nesbitt et al. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer
US20250009658A1 (en) Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
JP7330994B2 (ja) 治療用ナノ生物学的組成物による訓練免疫の促進
Li et al. Liposomal co-delivery of PD-L1 siRNA/Anemoside B4 for enhanced combinational immunotherapeutic effect
Jiang et al. Doxorubicin detoxification in healthy organs improves tolerability to high drug doses for enhanced antitumor therapy
JP2020511147A (ja) 薬剤負荷ナノ粒子が表面に結合したｃａｒ ｔ細胞の養子移入およびその使用
Ahmad et al. DHA-SBT-1214 taxoid nanoemulsion and anti–PD-L1 antibody combination therapy enhances antitumor efficacy in a syngeneic pancreatic adenocarcinoma model
Saraf et al. Targeting approaches for the diagnosis and treatment of cancer
Nadukkandy et al. Tracing new landscapes in the arena of nanoparticle-based cancer immunotherapy
Kanp et al. Exploring the potential of nanocarriers for cancer immunotherapy: insights into mechanism, nanocarriers, and regulatory perspectives
Lúcio et al. Functional lipid nanosystems in cancer
Kim et al. Cancer‐Specific and Pro‐Apoptotic PEGylated Liposomes Containing SMAC‐Mimetic Doxorubicin Prodrug for Safe High‐Dose Delivery in Pancreatic Cancer
Nakamura et al. In vivo cancer targeting of water-soluble taxol by folic acid immobilization
Bie et al. Tumor-Repopulating Cell-Derived Microparticle-Based Therapeutics Amplify the Antitumor Effect through Synergistic Inhibition of Chemoresistance and Immune Evasion
Reda et al. Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment
Cremolini et al. Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. Nanomaterials 2021, 11, 661
Adabi et al. Nanotechnology-based CAR strategies for tumor immunotherapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241015

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241015

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241015

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250107

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250613

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250613

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250616

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251009

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251009

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260306

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260317

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260317